In this issue:
ESMO Guidelines on the management of metastatic melanoma
ESMO Guidelines on the management of locoregional melanoma
Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma
RFS benefit of adjuvant pembrolizumab in high-risk stage III melanoma at 3-year median follow-up
Histopathological features of pCR predict RFS following neoadjuvant targeted therapy for metastatic melanoma
GEP tests for prognosis in localised cutaneous melanoma
Vitamin D intake is associated with decreased risk of ICI-induced colitis
Survival outcomes in an older US population with advanced melanoma and CNS metastases
Prognostic impact of extracapsular spread in melanoma lymphadenopathy
A prognostic nomogram for primary vulvar melanoma
Please login below to download this issue (PDF)